Browse the evidence

Dispensing rates for GLP-1 RAs are significantly lower for obesity (AOM) indications compared to diabetes (ADM) indications, with a large gap in 60-day initiation rates.

Even if prescribed, GLP-1 RAs for weight loss are less likely to be filled than those for diabetes, largely due to insurance coverage issues. If you are prescribed an AOM GLP-1 RA, proactively check your insurance coverage and explore assistance programs to ensure you can access the medication.

Dispensing rates for GLP-1 RAs are lower in patients aged 65+ compared to those aged 18-64, particularly for AOM indications.

Older adults (65+) are less likely to fill GLP-1 RA prescriptions for weight loss compared to younger adults, largely due to Medicare not covering these medications. If you are 65 or older, discuss alternative coverage options or patient assistance programs with your healthcare provider.

Triple agonists targeting GLP-1, GIP, and Glucagon receptors improve energy expenditure and restore body weight in diet-induced obesity models more effectively than dual or mono-agonists.

Triple hormone agonists (GLP-1/GIP/Glucagon) are in development and show promise in animal studies for boosting energy expenditure and weight loss beyond what dual agonists achieve. They are not yet standard clinical care.

GIP receptor agonism contributes to insulin sensitivity independently of weight loss by promoting glucose capture in white adipose tissue and catabolism of branched-chain amino acids in brown adipose tissue.

The addition of GIP receptor activation in dual agonists may help improve insulin sensitivity through metabolic pathways in fat tissue, independent of just losing weight.

Reducing saturated fat intake has little or no effect on all-cause mortality, cardiovascular mortality, or cancer deaths in adults.

While reducing saturated fat is excellent for preventing heart attacks and strokes, you should not expect it to drastically extend your lifespan on its own. Focus on the quality of life and prevention of non-fatal cardiovascular events as the primary benefit.

Adjunctive liraglutide 1.8 mg for 6 months following laparoscopic adjustable gastric banding (LAGB) provides no significant additional improvement in HbA1c or body weight compared to LAGB alone, and cessation of therapy leads to significant weight regain and worsening glycemic control relative to placebo.

If you have had a gastric band and are considering adding Liraglutide (Victoza) for 6 months, current evidence suggests it will not provide extra weight loss or blood sugar benefits during that time, and you may regain more weight after stopping it compared to not taking it. This does not rule out other GLP-1 drugs (like Semaglutide) or longer durations, but for this specific protocol, it is not recommended.

Daily consumption of a multi-ingredient supplement (whey protein, creatine, vitamin D, n-3 PUFA) for 7 weeks does not significantly alter resting or acute exercise-stimulated myofibrillar protein synthesis (MyoPS) in overweight older men compared to a control beverage.

For older overweight men, simply adding a multi-ingredient supplement (protein, creatine, vitamins) twice daily for several weeks does not necessarily boost muscle protein synthesis rates beyond what the body naturally does with exercise. Focus on consistent resistance training rather than expecting supplements to automatically amplify muscle growth signals.

A lifestyle pattern characterized by high consumption of food, alcohol, and cigarettes is associated with higher triglycerides, gamma-glutamyl transpeptidase (GTP), and diastolic blood pressure in T2DM patients.

For T2DM patients, high intake of alcohol, cigarettes, and large meals contributes to liver stress and high triglycerides. Reducing these specific behaviors can improve liver enzyme levels and blood pressure, even if blood sugar control remains stable.

Semaglutide therapy in older adults with type 2 diabetes accelerates muscle mass loss and functional decline, with higher doses and lower baseline muscle mass predicting greater loss.

If you are taking Semaglutide and are over 65 with diabetes, monitor your muscle strength. The medication can cause muscle loss, especially at higher doses. To counter this, focus on resistance training and adequate protein intake, and discuss dose adjustments with your doctor if you notice weakness.

Social media platforms (Instagram, TikTok) misrepresent semaglutide by promoting off-label weight loss use while omitting common adverse effects like gastrointestinal disorders, leading to unreflected medication use and supply shortages for indicated patients.

If you are considering semaglutide for weight loss, understand that it is a prescription medication with significant side effects, primarily gastrointestinal issues. Social media often omits these risks. Consult a healthcare provider to ensure it is appropriate for you and to avoid contributing to shortages for diabetic patients.

Enhancing insulin signaling specifically in adipose tissue improves obesity-related metabolic disorders by promoting healthy fat expansion and preventing ectopic fat accumulation, whereas enhancing insulin signaling in the liver exacerbates metabolic dysfunction.

Treating obesity-related metabolic issues requires targeting the right tissue. Simply boosting insulin systemically can be harmful, particularly to the liver. Future therapies must distinguish between adipose tissue (where boosting insulin helps store fat safely) and the liver (where boosting insulin worsens fat accumulation). Current clinical focus remains on lifestyle changes and existing drugs that improve sensitivity, but the research highlights the need for tissue-specific drugs.

Tirzepatide treatment in high-fat diet-induced metabolic dysfunction-associated fatty liver disease (MAFLD) mice significantly reduces hepatic lipid accumulation and liver damage by downregulating fatty acid uptake proteins (Cd36, Fabp2/4) and upregulating cholesterol efflux regulators (Hnf4a, Abcg5, Abcg8).

For individuals with fatty liver disease, tirzepatide (a dual GIP/GLP-1 agonist) has been shown in preclinical models to reduce liver fat and inflammation. It works by decreasing fatty acid uptake and increasing cholesterol excretion. While promising, these results are from mice, and human clinical data is needed to confirm efficacy and safety for liver health specifically.

Laparoscopic sleeve gastrectomy reduces the leptin-to-adiponectin ratio (LAR) in adults with severe obesity, which serves as a marker for improved insulin sensitivity and reduced cardiovascular risk.

For individuals with severe obesity considering sleeve gastrectomy, expect a significant improvement in insulin sensitivity, measured by the leptin-to-adiponectin ratio, within a year. This hormonal shift is a key driver of metabolic health improvement, potentially reducing the need for diabetes medications. While weight loss is substantial, the hormonal changes, particularly increased adiponectin, are critical for long-term metabolic benefits.

Current standard-of-care structured lifestyle modification (500 kcal deficit + 150 min activity) added to obesity pharmacotherapy lacks evidence of improving drug response and may act as a barrier to care by reinforcing stigma.

If you are starting obesity medication, you do not need to complete a mandatory lifestyle program to access or benefit from it. Current evidence does not show that mandatory calorie counting and exercise improve drug results. Focus on your health and well-being; if you choose to make lifestyle changes, do so for yourself, not as a requirement for your medication.

Pharmacological activation of brown adipose tissue (BAT) and induction of 'browning' in white adipose tissue (WAT) via agents such as β3-adrenergic receptor agonists, thyroid receptor agonists, and GLP-1-based multi-agonists enhances energy expenditure and improves metabolic parameters, offering a potential therapeutic avenue for obesity management.

This research suggests that certain medications (like GLP-1 agonists or specific receptor agonists) may help manage obesity not just by suppressing appetite, but by actively turning on your body's internal heating system (brown fat). This process burns energy as heat, which can improve blood sugar and lipid levels. While this might not always lead to massive weight loss on its own, it addresses the metabolic slowdown that often hinders long-term weight management.

Obesity-associated low-grade inflammation and adipose tissue dysfunction can induce resistance to β3-adrenergic receptor agonists (like CL316243) by suppressing β3-AR expression via the EPAC/RAP2A signaling pathway, thereby blunting thermogenic efficacy.

If you have obesity-related inflammation, standard fat-burning medications that target specific receptors (like β3-agonists) might be less effective because your body's inflammatory state can block these receptors. This highlights why some people don't respond to certain treatments and why newer drugs with different mechanisms might be needed.

Tirzepatide demonstrates potential kidney-protective effects by slowing the decline in eGFR and reducing urinary albumin-to-creatinine ratio (UACR) compared to insulin glargine.

While not yet a primary indication, early data suggests tirzepatide may help protect kidney function in T2D patients, potentially slowing kidney disease progression compared to insulin. This benefit is observed even in patients already taking other kidney-protective medications.

SGLT2 inhibitors reduce epicardial fat volume independently of significant weight loss, suggesting a direct lipolytic effect on epicardial tissue.

SGLT2 inhibitors are a key pharmacological option for HFpEF patients. They reduce epicardial fat directly, which may improve heart mechanics and reduce hospitalizations. Discuss with your doctor if SGLT2 inhibitors are appropriate for your condition.

Patients with active psychiatric disorders, particularly depression, may exhibit lower response rates to semaglutide and are at risk of weight gain during treatment.

If you have active depression or other psychiatric conditions, monitor your weight closely when starting semaglutide, as some patients may not lose weight or may even gain weight.

BGM0504, a GLP-1R/GIPR dual agonist with optimized acylation, demonstrates superior glycemic control, weight loss, and liver health improvements compared to Tirzepatide in diabetic and NASH mouse models.

BGM0504 is an experimental dual-agonist peptide designed to treat diabetes and obesity more effectively than existing drugs like Tirzepatide. In animal studies, it lowered blood sugar and body weight with fewer side effects on liver health. It is not yet available for human use.

A high-carbohydrate diet (CHORD) commonly prescribed for CPTII deficiency may be detrimental long-term by causing hyperinsulinemia, which inhibits CPT enzymes and diverts fatty acids to storage, potentially worsening insulin resistance and metabolic health.

Current advice to eat a very high-carb, low-fat diet might be hurting your long-term health. Try shifting to a moderate-carb diet (50-55% of calories) with higher protein (25-30%). This helps lower insulin levels, which may improve your body's ability to manage fatty acids and reduces the risk of insulin resistance.

Bariatric surgery (Roux-en-Y gastric bypass) significantly reduces circulating microvesicles (MVs) of monocyte and endothelial origin, specifically those expressing the CD36 scavenger receptor, within three months post-surgery.

For patients undergoing Roux-en-Y gastric bypass, significant reductions in inflammatory vascular markers (specifically CD36-bearing microvesicles from monocytes and endothelial cells) occur within just three months. This suggests that the surgery rapidly alleviates endothelial stress and low-grade inflammation associated with obesity, potentially reducing long-term cardiovascular risk beyond just weight loss.

Non-surgical weight management programs (WMPs) for adults with severe obesity (BMI ≥ 35 kg/m2) lack a clear consensus on cost-effectiveness, largely due to short-term study durations and heterogeneous definitions of usual care.

For individuals with severe obesity (BMI ≥ 35), non-surgical weight management programs exist but their cost-effectiveness is not clearly established. Most studies are short-term and do not capture long-term health outcomes. It is important to consult with healthcare providers to understand the potential benefits and costs of various non-surgical options, including lifestyle changes, VLCDs, and pharmacotherapy, as the evidence is heterogeneous.

Quercetin supplementation has no significant effect on Interleukin-6 (IL-6) concentrations after exercise.

Do not expect quercetin to significantly lower IL-6 levels post-exercise based on current meta-analytic data.